A Phase 2a, Open-Label, Randomized Study In Treatment-Naive, Sputum Smear Positive Subjects With Drug-Sensitive Pulmonary Tuberculosis To Assess Early Bactericidal Activity (EBA) And Whole Blood Activity (WBA) Of PNU-100480 (PF-02341272)
Phase of Trial: Phase II
Latest Information Update: 02 Feb 2016
At a glance
- Drugs Sutezolid (Primary) ; Linezolid; Rifampicin/isoniazid/pyrazinamide/ethambutol
- Indications Pulmonary tuberculosis
- Focus Therapeutic Use
- 30 Aug 2013 NCT record has updated the sponsor to Sequella.
- 27 Jul 2012 Results presented at the 19th International AIDS Conference.
- 30 Apr 2012 Actual patient number changed from 58 to 59 as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History